Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: To find a complete list of Publications, please see listing here.
Found 19 results
Filters: Author is Howard, Alan [Clear All Filters]
“Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.”, J Clin Invest, vol. 133, no. 15, 2023.
, “Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.”, Front Immunol, vol. 13, p. 966301, 2022.
, “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
, “Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.”, Transplant Cell Ther, vol. 29, no. 3, pp. 166.e1-166.e10, 2022.
, ,
“Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
, “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
, “Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.
, “Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.”, Biol Blood Marrow Transplant, vol. 26, no. 10, pp. e247-e255, 2020.
, “Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
, “A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation.”, Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
, “Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clini”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2143-2151, 2019.
, “Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation.”, Blood Adv, vol. 3, no. 15, pp. 2250-2263, 2019.
, “Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.”, Biol Blood Marrow Transplant, vol. 25, no. 3, pp. e89-e97, 2019.
, “Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.”, Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
, “The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.”, Biol Blood Marrow Transplant, vol. 24, no. 7, pp. 1322-1340, 2018.
, “Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.”, Br J Haematol, vol. 178, no. 5, pp. 816-819, 2017.
, “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
, “Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.”, J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
,